- Home
- XXI vs WVE Comparison
XXI vs WVE Comparison
Compare XXI & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XXI | WVE |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | XXI | WVE |
|---|---|---|
| Price | $6.70 | $13.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $31.47 |
| AVG Volume (30 Days) | 784.0K | ★ 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $119.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $5.61 | $5.28 |
| 52 Week High | $11.49 | $21.73 |
Technical Indicators
Market Signals| Indicator | XXI | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 47.54 |
| Support Level | $5.79 | $12.53 |
| Resistance Level | $9.97 | $14.56 |
| Average True Range (ATR) | 0.36 | 0.79 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 71.24 | 23.84 |
Price Performance
Historical ComparisonAbout XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc has no operation history.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.